Background
Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation is a common molecular event with an approximate incidence of 25% in acute myeloid leukaemia (AML) [
1]. High allelic ratio (≥ 0.5) of FLT3-ITD is associated with a very poor prognosis in both adults and children, and are rarely cured by chemotherapy alone [
2,
3]. Incorporation of FLT3 inhibitors with chemotherapy or haematopoietic stem cell transplantation has significantly improved the prognosis of FLT3-ITD-positive AML in recent years [
4‐
6], but high incidence of leukaemia relapse remains a problem to be solved [
2,
3]. Resistance to FLT3 inhibitors plays an important role in leukemia relapse [
2,
7,
8]. The resistance mechanisms are known to mainly include overexpression of oncogenic kinases, FLT3 ligand overproduction, bone marrow micro-environment (BME)-mediated protection and acquired resistant mutation [
2,
7].
Autophagy is an adaptive survival mechanism that is essential for cellular homeostasis in response to various stresses [
9]. More and more studies [
10‐
12] have linked alteration of autophagy with cancer initiation, progression and treatment resistance, including leukemia, thus autophagy has been shown to be a key therapeutic target. Most recently, Heydt et al. [
13] reported that FLT3-ITD mutation increased basal autophagy to support leukemic cells survival; also autophagy inhibition overcame FLT3 inhibitor resistance in vitro and vivo, suggesting autophagy might involve in the development and progression of FLT3-ITD-positive AML. However, in this AML subtype, how autophagy is activated to induce resistance to FLT3 inhibitors, and how it mediates the resistance remains unclear. In this study, we mainly explored the correlation of autophagy with FLT3 inhibitor resistance, the inductive effect of acquired mutation and BME on autophagy, and the mechanism of autophagy mediating resistance.
Materials and methods
Reagents and antibodies
Sorafenib (CAS #475207-59-1) and quizartinib (AC220, CAS #950769-58-1) were purchased from Selleck. Chloroquince (CQ, CAS #50-63-5) was bought from Sigma. The antibodies against human-phosphorylated (p)-p44/42 MAPK (ERK1/2, Thr202/Tyr204, CAS #4370), p-FLT3 (Tyr589/591, CAS ##60413), p-mTOR (Ser2448, CAS #5536), p-S6K (Ser240/244, CAS #2215), mTOR (CAS ##2983), S6K (CAS #9202), Beclin-1 (CAS #4122), LC3B (CAS #3868), ATG5 (D5G3, CAS #9980), p62/SQSTM1 (CAS #5114), c-Myc (D84C12, CAS #5605) and cleaved caspase-3 (Asp175, CAS #9661) were purchased from Cell Signaling Technology. Against ERK2 (CAS #sc-1647) and FLT3 (CAS #sc-19635) were from Santa Cruz Biotechnology. Anti-GAPHD (CAS #G9545) was purchased from Millipore Sigma.
AML patient samples and FLT3 mutant cell lines
Six patients with FLT3-ITD-positive AML were included from the ClinicalTrials (NCT02474290). The detail of clinical characteristics and treatment protocol had been reported [
14]. Bone marrow samples were obtained from those patients at diagnosis, continued complete response (CCR) or relapsed after written informed consents were gotten according to the institutional guidelines of Medicine Institutional Review Boards of Nanfang Hospital, Southern Medical University. The mononuclear (MNC) cells in these samples were purified by Ficoll-Hypaque (Sigma-Aldrich) density gradient centrifugation, and then cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS).
Mesenchymal stem cells (MSCs), were obtained from bone marrows of one of the patients above at leukemia relapse (case #3) and one at the status of CCR (case #2), and cultured at a density of 5,000 cells/cm2 in a-MEM, supplemented with 20% FCS, 1% l-glutamine, and 1% penicillin–streptomycin. The MSCs were used for co-culture experiments after passage.
The Ba/F3-ITD, Ba/F3-D835Y and Ba/F3-ITD + D835Y cell lines, and the human AML cell line MOLM14 were all kindly provided by professor Andreeff Michael (Department of Leukemia Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX) in 2016. All cell lines were validated by short tandem repeat (STR) DNA fingerprinting using the AmpFISTR Identifiler Kit as described before [
15]. All cells were maintained in RPMI medium supplemented with 10% FCS.
Cell viability and apoptosis assays
Cell viability was assessed using the trypan blue dye exclusion method, and apoptosis was determined via flow cytometry (FACS) by Annexin V positivity as described [
16].
For measuring apoptosis induction in the leukemia cells co-cultured with MSCs, the cells were trypsinized and stained with CD90-PE, CD45-APC and Annexin V-FITC (all from BD Biosciences), and apoptosis was assessed by measuring Annexin V-FITC positivity after excluding the CD90 + CD45—(used as a MSC marker) cell population.
Transmission electron microscopy
According to our previous report [
17], samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, then washed in 0.1 M sodium cacodylate buffer and treated with 0.1% Millipore-filtered cacodylate buffered tannic acid, postfixed with 1% buffered osmium, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60 ℃ oven for approximately 3 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 80 kV. Micrographs were taken at 7500 × or 50,000 × magnification.
Immunoblotting analyses
The cells were treated with the indicated agents and then collected in lysis buffer. Phosphorylation and total protein levels were determined using Odyssey Infrared Imaging System (LI-COR Biosciences).
Statistical analyses
The data are presented as the means ± SD of triplicate samples or assays. The statistical analyses were performed using unpaired Student t test. A 2-sided Fisher exact test was used to determine statistical significance between different groups. A P value ≤ 0.05 was considered statistically significant.
Discussion
FLT3 inhibitor resistance is the important reason for leukemia relapse in FLT3-ITD-positive AML [
2,
7,
8]. In the present study, we revealed that, in FLT3-ITD-positive AML, FLT3 inhibitor resistant cells overexpressed autophagy; Autophagy was activated by acquired D835Y mutation or BME and then mediated FLT3 inhibitor resistance; Autophagy activation reduced the suppression efficacy of FLT3 inhibitors on FLT3 downstream signaling and then decreased their pro-apoptotic effect; Inhibition of autophagy enhanced the anti-leukemia effect of FLT3 inhibitors, partly overcame FLT3 inhibitor resistance,. Our data further supports that autophagy significantly involves in leukemia progression and resistance, could be a promising therapeutic target in FLT3-ITD-positive AML.
Our results accord with previous studies [
10‐
13,
20,
21], that autophagy is closely associated with resistance in AML, especially in the patients with FLT3-ITD mutation. Activation of cytoprotective autophagy is found in cytarabine-resistant AML cells, and blockade of autophagy markedly increases the cytotoxic effect of cytarabine [
21,
22]. Oncogenic FLT3-ITD increases autophagic flux to support AML cell survival and proliferation. Inhibition of autophagy overcomes FLT3 inhibitor resistance in FLT3-ITD-positive cells [
13,
23]. In our study, FLT3 inhibitor resistant leukemia cells showed significantly activating autophagy. When autophagy was inhibited, those resistant cells were sensitized to FLT3 inhibitors.
In this study, acquired D835Y mutation and BME were found to be important factors for stimulation of autophagy in FLT3-ITD-positive cells. As it is known that acquired mutation is the key factor for resistance to FLT3 inhibitors in FLT3-ITD-positive AML [
2,
7,
8]. Except for changing molecular conformation [
24], we revealed that, autophagy activation by acquired D835Y mutation could be an important mechanism for resistance. Inhibition of autophagy enhanced the anti-leukemia effect of sorafenib in leukemia cell lines and primary blasts with FLT3-ITD + D835Y mutation, which opens a window for overcoming FLT3 inhibitor resistance in AML with acquired D835 mutation. In addition, secondary mutation is acquired under clone selective pressure [
25]. Since autophagy is an adaptive survival mechanism for leukemia cells in response to various stresses [
9,
10,
12], the causal link between acquired mutation and autophagy activation remains open. In line with stimulation of cytoprotective autophagy against cytarabine/anthracycline combination by BME [
19], our study also observed BME induced cytoprotective autophagy against FLT3 inhibitors. The way of BME stimulating autophagy needs further research.
Many studies [
26‐
28] show that autophagy selectively eliminates impaired or extra intracellular contents, and then supports the maintenance and self-renewal capacity of cancer stem cells, acting as a regulatory or cytoprotective adaptive mechanism, leading to malignant progression of different types of cancers including AML. In FLT3-ITD-positive AML, FLT3-ITD mutation increases basal autophagy to support leukemic cell survival and proliferation via transcription factor ATF4 (activating transcription factor 4). Inhibition of autophagy or ATF4 enhances the anti-leukemia effect of FLT3 inhibitors [
13]. Yet, how autophagy mediates FLT3 inhibitor resistance remains unclear. In our study, we found that the suppression of sorafenib on FLT3 downstream signaling and the induction of pro-apoptotic effect in FLT3-ITD-positive cells were weaken by autophagy activated by acquired D835Y mutation or MSCs. After autophagy was inhibited, sorafenib more markedly suppressed FLT3 downstream signaling and promoted cell death, and finally overcame FLT3 inhibitor resistance mediated by acquired mutation or MSCs, suggesting that autophagy overexpression might bypass activate FLT3 downstream signaling to eliminate the suppressive effect of FLT3 inhibitors on FLT3 pathway, which calls for further study.
More and more studies have demonstrated autophagy could be a promising therapeutic target for overcoming drug resistance in AML [
11‐
13,
19,
20]. As a survival mechanism to resist cytotoxic stress, leukemia cells are found to increase autophagy during the treatment of chemotherapy including cytarabine and daunorubicin [
12,
19,
29], or targeted therapy such as BET inhibitors [
20], histone methyltransferase inhibitors [
30], BCL2 inhibitors [
31], to counteract therapeutic effect. Inhibition of autophagy could sensitize leukemia cells to these agents. In the present study, autophagy was also observed to be activated and mediated resistance to FLT3 inhibitors during the treatment in FLT3-ITD-positive AML. Targeted suppression of autophagy with CQ enhanced the anti-leukemia effect of FLT3 inhibitors, and eliminated acquired resistance mediated by acquired D835Y mutation or MSCs. In agreement with our data, Qiu et al. reported combination of quizartinib with autophagy inhibitor Lys05 markedly improved proliferation inhibition and apoptosis induction in comparison with quizartinib alone [
23]. Heydt et al. showed autophagy suppression by SAR405 or shRNA against ATG12 overcame quizartinib resistance in MOLM-14 cells with FLT3-D835Y mutation in vitro and vivo [
13]. All of these further support autophagy should be a critical target in AML therapy, especially in overcoming drug resistance.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.